NDSN Q2 2026 Earnings Call Summary

Summary of Nordson Corporation Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Sales: Record sales of $741 million, an 8% increase year-over-year, with 7% organic growth.
EBITDA: $235 million, representing 32% of sales, also a second quarter record.
Adjusted EPS: $2.86, an 18% increase from $2.42 in the prior year.
Free Cash Flow: $170 million, with a conversion rate exceeding 100% of net income.
Net Income: GAAP net income of $117 million or $2.09 per share.
Debt: Net debt reduced to approximately $1.8 billion, with a leverage ratio of 1.9x.

2. Strategic Updates and Business Highlights

Segment Performance:
- Industrial Precision Solutions (IPS): Sales of $350 million, a 10% increase; EBITDA margin at 35%.
- Medical and Fluid Solutions: Sales of $213 million, up 5%; EBITDA margin at 37%.
- Advanced Technology Solutions (ATS): Record sales of $178 million, a 10% increase; EBITDA margin at 27%.
Acquisition: Acquired CapstanAG, enhancing the precision agriculture portfolio, valued at 9x adjusted EBITDA.
Capital Allocation: Invested $10 million in capital projects, paid $46 million in dividends, and repurchased $43 million in shares.

3. Forward Guidance and Outlook

Q3 Guidance: Expected sales between $760 million to $790 million; adjusted EPS forecasted between $2.95 to $3.15.
Full Year Guidance: Sales projected between $2.930 billion to $3.010 billion; adjusted EPS forecasted between $11.30 to $11.80.
Backlog: Increased by 18% year-over-year, indicating strong order entry momentum across all segments.

4. Bad News, Challenges, or Points of Concern

Margin Pressures: Some compression in EBITDA margins due to inflationary pressures and operational inefficiencies in the medical segment.
Regulatory Changes: A material change in one medical product line led to near-term operational inefficiencies.
Market Uncertainties: Potential macroeconomic headwinds could impact demand; management remains cautious about future economic conditions.

5. Notable Q&A Insights

Medical Segment Growth: Management expressed confidence in returning to normalized growth rates of 6%-8% for medical products, despite some near-term headwinds.
Semiconductor Market Positioning: Strong backlog growth in ATS, attributed to diversification and innovation in response to customer needs in the semiconductor space.
Industrial Segment Dynamics: The mix of aftermarket sales versus systems remains stable, with no significant changes in customer CapEx decisions.
M&A Environment: Active pipeline for acquisitions, with a focus on strategic and bolt-on opportunities, particularly in medical and technology sectors.

Overall, Nordson demonstrated strong financial performance in Q2 2026, with robust growth across all segments and strategic initiatives supporting future growth, despite facing some operational challenges and macroeconomic uncertainties.

NDSN — Nordson Corporation